Search

Your search keyword '"Ningarhari, Massih"' showing total 44 results
Start Over Author "Ningarhari, Massih"
44 results on '"Ningarhari, Massih"'

1. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma

Author

Calderaro, Julien, Ghaffari Laleh, Narmin, Zeng, Qinghe, Maille, Pascale, Favre, Loetitia, Pujals, Anaïs, Klein, Christophe, Bazille, Céline, Heij, Lara R., Uguen, Arnaud, Luedde, Tom, Di Tommaso, Luca, Beaufrère, Aurélie, Chatain, Augustin, Gastineau, Delphine, Nguyen, Cong Trung, Nguyen-Canh, Hiep, Thi, Khuyen Nguyen, Gnemmi, Viviane, Graham, Rondell P., Charlotte, Frédéric, Wendum, Dominique, Vij, Mukul, Allende, Daniela S., Aucejo, Federico, Diaz, Alba, Rivière, Benjamin, Herrero, Astrid, Evert, Katja, Calvisi, Diego Francesco, Augustin, Jérémy, Leow, Wei Qiang, Leung, Howard Ho Wai, Boleslawski, Emmanuel, Rela, Mohamed, François, Arnaud, Cha, Anthony Wing-Hung, Forner, Alejandro, Reig, Maria, Allaire, Manon, Scatton, Olivier, Chatelain, Denis, Boulagnon-Rombi, Camille, Sturm, Nathalie, Menahem, Benjamin, Frouin, Eric, Tougeron, David, Tournigand, Christophe, Kempf, Emmanuelle, Kim, Haeryoung, Ningarhari, Massih, Michalak-Provost, Sophie, Gopal, Purva, Brustia, Raffaele, Vibert, Eric, Schulze, Kornelius, Rüther, Darius F., Weidemann, Sören A., Rhaiem, Rami, Pawlotsky, Jean-Michel, Zhang, Xuchen, Luciani, Alain, Mulé, Sébastien, Laurent, Alexis, Amaddeo, Giuliana, Regnault, Hélène, De Martin, Eleonora, Sempoux, Christine, Navale, Pooja, Westerhoff, Maria, Lo, Regina Cheuk-Lam, Bednarsch, Jan, Gouw, Annette, Guettier, Catherine, Lequoy, Marie, Harada, Kenichi, Sripongpun, Pimsiri, Wetwittayaklang, Poowadon, Loménie, Nicolas, Tantipisit, Jarukit, Kaewdech, Apichat, Shen, Jeanne, Paradis, Valérie, Caruso, Stefano, and Kather, Jakob Nikolas

Published
2023
Full Text
View/download PDF

2. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

Author

Allende, Daniela S, Amaddeo, Giuliana, Argemi, Josepmaria, Baulande, Sylvain, Beaufrère, Aurélie, Bermúdez-Ramos, María, Boulagnon-Rombi, Camille, Boursier, Jérôme, Bruges, Léa, Calderaro, Julien, Campani, Claudia, Caruso, Stefano, Casadei-Gardini, Andrea, Castano Garcia, Andres, Chan, Stephen Lam, D'Alessio, Antonio, Di Tommaso, Luca, Diaz, Alba, Digklia, Antonia, Dufour, Jean-François, Garcia-Porrero, Guillermo, Ghaffari Laleh, Narmin, Gnemmi, Viviane, Gopal, Purva, Graham, Rondell P., Heurgué, Alexandra, Iavarone, Massimo, Iñarrairaegui, Mercedes, Kather, Jakob Nikolas, Klein, Christophe, Labgaa, Ismail, Lameiras, Sonia, Legoix, Patricia, Lequoy, Marie, Leung, Howard Ho-Wai, Loménie, Nicolas, Maggioni, Marco, Maille, Pascale, Marín-Zuluaga, Juan Ignacio, Mendoza-Pacas, Guillermo, Michalak, Sophie, Mínguez, Beatriz, El Nahhas, Omar S M, Nault, Jean-Charles, Navale, Pooja, Ningarhari, Massih, Paradis, Valérie, Park, Young Nyun, Pawlotsky, Jean-Michel, Pedica, Federica, Perbellini, Riccardo, Peter, Simon, Pinato, David James, Pinter, Matthias, Radu, Pompilia, Regnault, Hélène, Reig, Maria, Rela, Mohamed, Rhee, Hyungjin, Rimassa, Lorenza, Rimini, Margherita, Salcedo, María Teresa, Sangro, Bruno, Scheiner, Bernhard, Sempoux, Christine, Su, Tung-Hung, Torres, Callie, Tran, Nguyen H, Trépo, Eric, Varela, Maria, Verset, Gontran, Vij, Mukul, Vogel, Arndt, Wendum, Dominique, Zeng, Qinghe, and Ziol, Marianne

Published
2023
Full Text
View/download PDF

4. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma

Author

Calderaro, Julien, Di Tommaso, Luca, Maillé, Pascale, Beaufrère, Aurélie, Nguyen, Cong Trung, Heij, Lara, Gnemmi, Viviane, Graham, Rondell P., Charlotte, Frédéric, Chartier, Suzanne, Wendum, Dominique, Vij, Mukul, Allende, Daniela, Diaz, Alba, Fuster, Carla, Rivière, Benjamin, Herrero, Astrid, Augustin, Jérémy, Evert, Katja, Calvisi, Diego Francesco, Leow, Wei Qiang, Leung, Howard Ho Wai, Bednarsch, Jan, Boleslawski, Emmanuel, Rela, Mohamed, Chan, Anthony Wing-Hung, Forner, Alejandro, Reig, Maria, Pujals, Anaïs, Favre, Loetitia, Allaire, Manon, Scatton, Olivier, Uguen, Arnaud, Trépo, Eric, Sanchez, Lukas Otero, Chatelain, Denis, Remmelink, Myriam, Boulagnon-Rombi, Camille, Bazille, Céline, Sturm, Nathalie, Menahem, Benjamin, Frouin, Eric, Tougeron, David, Tournigand, Christophe, Kempf, Emmanuelle, Kim, Haeryoung, Ningarhari, Massih, Michalak-Provost, Sophie, Kather, Jakob Nikolas, Gouw, Annette S.H., Gopal, Purva, Brustia, Raffaele, Vibert, Eric, Schulze, Kornelius, Rüther, Darius F., Weidemann, Sören A., Rhaiem, Rami, Nault, Jean-Charles, Laurent, Alexis, Amaddeo, Giuliana, Regnault, Hélène, de Martin, Eleonora, Sempoux, Christine, Navale, Pooja, Shinde, Jayendra, Bacchuwar, Ketan, Westerhoff, Maria, Lo, Regina Cheuk-Lam, Sebbagh, Mylène, Guettier, Catherine, Lequoy, Marie, Komuta, Mina, Ziol, Marianne, Paradis, Valérie, Shen, Jeanne, and Caruso, Stefano

Published
2022
Full Text
View/download PDF

5. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study

Author

Meiller, Clément, Cao, Qian, Hirsch, Théo Z., Rebouissou, Sandra, Degré, Delphine, Otero Sanchez, Lukas, Rosewick, Nicolas, Quertinmont, Eric, Desille-Dugast, Mireille, François-Vié, Muriel, Moins, Cécile, Leteurtre, Emmanuelle, Lassailly, Guillaume, Ningarhari, Massih, Boleslawski, Emmanuel, Cottet, Vanessa, Trépo, Eric, Caruso, Stefano, Yang, Jie, Imbeaud, Sandrine, Couchy, Gabrielle, Bayard, Quentin, Letouzé, Eric, Ganne-Carrié, Nathalie, Moreno, Christophe, Oussalah, Abderrahim, Féray, Cyrille, Blanc, Jean Frédéric, Clément, Bruno, Hillon, Patrick, Boursier, Jérôme, Paradis, Valérie, Calderaro, Julien, Gnemmi, Viviane, Nault, Jean-Charles, Guéant, Jean-Louis, Devière, Jacques, Archambeaud, Isabelle, Vitellius, Carole, Turlin, Bruno, Bronowicki, Jean-Pierre, Gustot, Thierry, Sutton, Angela, Ziol, Marianne, Nahon, Pierre, and Zucman-Rossi, Jessica

Published
2022
Full Text
View/download PDF

6. SAT-439-YI Socioeconomic deprivation is independently associated with hepatocellular carcinoma mortality in a western european country with single-payer healthcare

Author

Ningarhari, Massih, primary, Lacour, Alexandre, additional, Dauchy, Simon, additional, Genin, Michael, additional, Bruandet, Amelie, additional, Cattan, Stéphane, additional, Wandji, Line Carolle Ntandja, additional, Lemaître, Elise, additional, Canva, Valérie, additional, Louvet, Alexandre, additional, Mathurin, Philippe, additional, Dharancy, Sébastien, additional, and Lassailly, Guillaume, additional

Published
2024
Full Text
View/download PDF

7. TOP-005 Immune checkpoint inhibitors after liver transplantation: the key role of immunosuppression management

Author

De Martin, Eleonora, primary, Antonini, Teresa, additional, Ningarhari, Massih, additional, Hilleret, Marie-Noëlle, additional, Allaire, Manon, additional, Del Bello, Arnaud, additional, Amaddeo, Giuliana, additional, Besch, Camille, additional, Cransac, Martine Neau, additional, Jaillais, Anais, additional, Ollivier-Hourmand, Isabelle, additional, Dharancy, Sébastien, additional, Decaens, Thomas, additional, Conti, Filomena, additional, Saliba, Faouzi, additional, Rosmorduc, Olivier, additional, Dumortier, Jérôme, additional, and Coilly, Audrey, additional

Published
2024
Full Text
View/download PDF

8. Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules

Author

Lassailly, Guillaume, Bou Saleh, Mohamed, Leleu-Chavain, Natascha, Ningarhari, Massih, Gantier, Emilie, Carpentier, Rodolphe, Artru, Florent, Gnemmi, Viviane, Bertin, Benjamin, Maboudou, Patrice, Betbeder, Didier, Gheeraert, Céline, Maggiotto, François, Dharancy, Sébastien, Mathurin, Philippe, Louvet, Alexandre, and Dubuquoy, Laurent

Published
2019
Full Text
View/download PDF

9. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

Author

Zeng, Qinghe, primary, Klein, Christophe, additional, Caruso, Stefano, additional, Maille, Pascale, additional, Allende, Daniela S, additional, Mínguez, Beatriz, additional, Iavarone, Massimo, additional, Ningarhari, Massih, additional, Casadei-Gardini, Andrea, additional, Pedica, Federica, additional, Rimini, Margherita, additional, Perbellini, Riccardo, additional, Boulagnon-Rombi, Camille, additional, Heurgué, Alexandra, additional, Maggioni, Marco, additional, Rela, Mohamed, additional, Vij, Mukul, additional, Baulande, Sylvain, additional, Legoix, Patricia, additional, Lameiras, Sonia, additional, Amaddeo, Giuliana, additional, Argemi, Josepmaria, additional, Beaufrère, Aurélie, additional, Bermúdez-Ramos, María, additional, Boursier, Jérôme, additional, Bruges, Léa, additional, Calderaro, Julien, additional, Campani, Claudia, additional, Castano Garcia, Andres, additional, Chan, Stephen Lam, additional, D'Alessio, Antonio, additional, Di Tommaso, Luca, additional, Diaz, Alba, additional, Digklia, Antonia, additional, Dufour, Jean-François, additional, Garcia-Porrero, Guillermo, additional, Ghaffari Laleh, Narmin, additional, Gnemmi, Viviane, additional, Gopal, Purva, additional, Graham, Rondell P., additional, Iñarrairaegui, Mercedes, additional, Kather, Jakob Nikolas, additional, Labgaa, Ismail, additional, Lequoy, Marie, additional, Leung, Howard Ho-Wai, additional, Loménie, Nicolas, additional, Marín-Zuluaga, Juan Ignacio, additional, Mendoza-Pacas, Guillermo, additional, Michalak, Sophie, additional, El Nahhas, Omar S M, additional, Nault, Jean-Charles, additional, Navale, Pooja, additional, Paradis, Valérie, additional, Park, Young Nyun, additional, Pawlotsky, Jean-Michel, additional, Peter, Simon, additional, Pinato, David James, additional, Pinter, Matthias, additional, Radu, Pompilia, additional, Regnault, Hélène, additional, Reig, Maria, additional, Rhee, Hyungjin, additional, Rimassa, Lorenza, additional, Salcedo, María Teresa, additional, Sangro, Bruno, additional, Scheiner, Bernhard, additional, Sempoux, Christine, additional, Su, Tung-Hung, additional, Torres, Callie, additional, Tran, Nguyen H, additional, Trépo, Eric, additional, Varela, Maria, additional, Verset, Gontran, additional, Vogel, Arndt, additional, Wendum, Dominique, additional, Zeng, Qinghe, additional, and Ziol, Marianne, additional

Published
2023
Full Text
View/download PDF

12. Conventional cytotoxic chemotherapy for gastrointestinal cancer in patients with cirrhosis: A multicentre case–control study.

Author

Ningarhari, Massih, Bertez, Marlène, Ploquin, Anne, Bertrand, Nicolas, Desauw, Christophe, Cattan, Stéphane, Catala, Pascale, Vandamme, Hélène, Cheymol, Claire, Truant, Stéphanie, Lassailly, Guillaume, Louvet, Alexandre, Mathurin, Philippe, Dharancy, Sébastien, and Turpin, Anthony

Subjects
*GASTROINTESTINAL cancer, *CANCER chemotherapy, *CIRRHOSIS of the liver, *TERMINATION of treatment, *CASE-control method, *CANCER-related mortality
Abstract

Background & Aims: Progresses in management make a higher proportion of cirrhotic patients with gastrointestinal (GI) cancer candidates to chemotherapy. Data are needed on the safety and liver‐related events associated with the use of chemotherapy in these patients. Methods: Forty‐nine patients with cirrhosis receiving chemotherapy against GI cancer from 2013 to 2018 were identified in the French Health Insurance Database using ICD‐10 codes K70‐K74, and matched 1:2 to non‐cirrhotic controls (n = 98) on age, tumour type and type of treatment. Adverse events (AE), dose tapering, discontinuation rate, liver‐related events and survival rate were compared. Results: Patients with cirrhosis (Child–Pugh A 91%) more often received lower doses (38.8% vs 7.1%, p <.001), without significant differences in terms of grade 3/4 AE or dose tapering rates (29.6% vs. 36.7%; 22.3% vs 24.4%, respectively). Treatment discontinuation rate was higher in patients with cirrhosis (23.3% vs. 11.3%, p =.005). Child–Pugh (p =.007) and MELD (p =.025) scores increased under chemotherapy. Five patients with cirrhosis (10.2%) had liver decompensation within 12 months, and 17.2% of deaths in the cirrhosis group were liver‐related versus 0% in matched controls. WHO‐PS stage > 1 (HR 3.74, CI95%: 2.13–6.57, p <.001), TNM‐stage M1 (HR 3.61, CI 95%: 1.82–7.16, p <.001), non‐colorectal cancer (HR 1.73, CI 95%: 1.05–2.86, p =.032) and bilirubin higher than 5 mg/dL (HR 2.26, CI 95%: 1.39–3.70, p <.001) were independent prognostic factors of 2‐year mortality, whereas cirrhosis was not. Conclusions: Chemotherapy should be proposed only in patients with compensated cirrhosis with close monitoring of liver function. Dose management remains challenging. Multidisciplinary management is warranted to improve these patients' outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma

Author

Zeng, Qinghe, primary, Klein, Christophe, additional, Caruso, Stefano, additional, Maille, Pascale, additional, Allende, Daniela, additional, Minguez, Beatriz, additional, Iavarone, Massimo, additional, Ningarhari, Massih, additional, Gardini, Andrea Casadei, additional, Pedica, Federica, additional, Rimini, Margherita, additional, perbellini, Riccardo, additional, Boulagnon-Rombi, Camille, additional, Heurgue-berlot, Alexandra, additional, Maggioni, Marco, additional, Rela, Mohd., additional, Vij, Mukul, additional, Baulande, Sylvain, additional, Legoix, Patricia, additional, Lameiras, Sonia, additional, Labgaa, Ismail, additional, Sempoux, Christine, additional, Digkilia, Antonia, additional, Ghaffari-Laleh, Narmin, additional, Kather, Jakob Nikolas, additional, El Nahhas, Omar, additional, Navale, Pooja, additional, Torres, Callie, additional, Su, Tung-Hung, additional, Graham, Rondell, additional, Salcedo, María, additional, Bermúdez, María, additional, Tran, Nguyen H., additional, Pawlotsky, Jean-Michel, additional, Verset, Gontran, additional, Trépo, Eric, additional, Varela, Maria, additional, Castano-Garcia, Andrés, additional, Wendum, Dominique, additional, Amaddeo, Giuliana, additional, Regnault, Helene, additional, Lequoy, Marie, additional, Díaz, Alba, additional, Reig, María, additional, Radu, Pompilia, additional, Dufour, Jean-François, additional, Chan, Stephen, additional, Gopal, Purva, additional, Bruges, Léa, additional, Gnemmi, Viviane, additional, Nault, Jean Charles, additional, Rhee, Hyungjin, additional, Park, Young Nyun, additional, Iñarrairaegui, Mercedes, additional, Argemi, Josep Maria, additional, Sangro, Bruno, additional, D’Alessio, Antonio, additional, Scheiner, Bernhard, additional, Pinato, David J., additional, Pinter, Matthias, additional, Paradis, Valérie, additional, Beaufrère, Aurélie, additional, Peter, Simon, additional, Rimassa, Lorenza, additional, Di Tommaso, Luca, additional, Vogel, Arndt, additional, Michalak, Sophie, additional, Boursier, Jerome, additional, Loménie, Nicolas, additional, Ziol, Marianne, additional, and Calderaro, Julien, additional

Published
2023
Full Text
View/download PDF

14. Natural history and management of recurrent hepatocellular carcinoma after liver transplantation: a multicenter nationwide study

Author

Ningarhari, Massih, primary, Henry, Camille, additional, Boleslawski, Emmanuel, additional, Besch, Camille, additional, Faitot, François, additional, Assenat, Eric, additional, Herrero, Astrid, additional, Ursic-Bedoya, Jose, additional, Robin, Fabien, additional, Uguen, Thomas, additional, Antonini, Teresa, additional, Erard, Domitille, additional, Radenne, Sylvie, additional, Brusset, Bleuenn, additional, Decaens, Thomas, additional, Allaire, Manon, additional, Conti, Filomena, additional, Barraud, Hélène, additional, Elkrief, Laure, additional, Salamé, Ephrem, additional, Boillot, Olivier, additional, Dumortier, Jérôme, additional, Ntandja Wandji, Line Carolle, additional, Louvet, Alexandre, additional, Mathurin, Philippe, additional, Dharancy, Sebastien, additional, and Lassailly, Guillaume, additional

Published
2023
Full Text
View/download PDF

15. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.

Author

Zeng, Qinghe, Klein, Christophe, Caruso, Stefano, Maille, Pascale, Allende, Daniela S, Mínguez, Beatriz, Iavarone, Massimo, Ningarhari, Massih, Casadei-Gardini, Andrea, Pedica, Federica, Rimini, Margherita, Perbellini, Riccardo, Boulagnon-Rombi, Camille, Heurgué, Alexandra, Maggioni, Marco, Trepo, Eric, Vij, Mukul, Baulande, Sylvain, Legoix, Patricia, Lameiras, Sonia, HCC-AI study group, Bruges, Léa, Gnemmi, Viviane, Nault, Jean Charles, Campani, Claudia, Rhee, Hyungjin, Park, Young Nyun, Iñarrairaegui, Mercedes, Garcia-Porrero, Guillermo, Argemi, Josepmaria, Sangro, Bruno, D'Alessio, Antonio, Scheiner, Bernhard, Pinato, David James, Pinter, Matthias, Paradis, Valérie, Beaufrère, Aurélie, Peter, Simon, Rimassa, Lorenza, Di Tommaso, Luca, Vogel, Arndt, Michalak, Sophie, Boursier, Jérôme, Loménie, Nicolas, Ziol, Marianne, Calderaro, Julien, Zeng, Qinghe, Klein, Christophe, Caruso, Stefano, Maille, Pascale, Allende, Daniela S, Mínguez, Beatriz, Iavarone, Massimo, Ningarhari, Massih, Casadei-Gardini, Andrea, Pedica, Federica, Rimini, Margherita, Perbellini, Riccardo, Boulagnon-Rombi, Camille, Heurgué, Alexandra, Maggioni, Marco, Trepo, Eric, Vij, Mukul, Baulande, Sylvain, Legoix, Patricia, Lameiras, Sonia, HCC-AI study group, Bruges, Léa, Gnemmi, Viviane, Nault, Jean Charles, Campani, Claudia, Rhee, Hyungjin, Park, Young Nyun, Iñarrairaegui, Mercedes, Garcia-Porrero, Guillermo, Argemi, Josepmaria, Sangro, Bruno, D'Alessio, Antonio, Scheiner, Bernhard, Pinato, David James, Pinter, Matthias, Paradis, Valérie, Beaufrère, Aurélie, Peter, Simon, Rimassa, Lorenza, Di Tommaso, Luca, Vogel, Arndt, Michalak, Sophie, Boursier, Jérôme, Loménie, Nicolas, Ziol, Marianne, and Calderaro, Julien

Abstract

Clinical benefits of atezolizumab plus bevacizumab (atezolizumab-bevacizumab) are observed only in a subset of patients with hepatocellular carcinoma and the development of biomarkers is needed to improve therapeutic strategies. The atezolizumab-bevacizumab response signature (ABRS), assessed by molecular biology profiling techniques, has been shown to be associated with progression-free survival after treatment initiation. The primary objective of our study was to develop an artificial intelligence (AI) model able to estimate ABRS expression directly from histological slides, and to evaluate if model predictions were associated with progression-free survival., info:eu-repo/semantics/published

Published
2023

16. Management of alcohol‐related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines

Author

Louvet, Alexandre, Trabut, Jean-Baptiste, Moreno, Christophe, Moirand, Romain, Aubin, Henri-Jean, Ntandja Wandji, Line Carolle, Nourredine, Mikail, Ningarhari, Massih, Ganne-Carrié, Nathalie, Pageaux, Georges-Philippe, Bailly, François, Boursier, Jérôme, Daeppen, Jean-Bernard, Luquiens, Amandine, Nguyen-Khac, Eric, Anty, Rodolphe, Orban, Thomas, Donnadieu-Rigole, Hélène, Mallat, Ariane, Bureau, Christophe, Pariente, Emile-Alexandre, Paupard, Thierry, Benyamina, Amine, Perney, Pascal, Mathurin, Philippe, Rolland, Benjamin, CHU Lille, Hôpital Claude Huriez [Lille], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Hôpital Paul Brousse, Hospices Civils de Lyon (HCL), Hôpital Avicenne [AP-HP], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CHU Amiens-Picardie, Hôpital Archet 2 [Nice] (CHU), Hôpital Henri Mondor, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CH Dunkerque, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Service Universitaire d’Addictologie de Lyon [CH Le Vinatier, Bron] (Pôle MOPHA - SUAL), Centre Hospitalier le Vinatier [Bron], and for the Groupe collaboratif AFEF-SFA Maladie du foie liée à l'alcool

Subjects
Ethanol, Hepatology, alcohol, alcohol-related liver disease, Liver Diseases, [SDV]Life Sciences [q-bio], Humans, France, guidelines
Abstract

International audience; Excessive alcohol consumption is the leading cause of liver diseases in Western countries, especially in France. Alcohol-related liver disease (ARLD) is an extremely broad context and there remains much to accomplish in terms of identifying patients, improving prognosis and treatment, and standardising practices. The French Association for the Study of the Liver wished to organise guidelines together with the French Alcohol Society in order to summarise the best evidence available about several key clinical points in ARLD. These guidelines have been elaborated based on the level of evidence available in the literature and each recommendation has been analysed, discussed and voted by the panel of experts. They describe how patients with ARLD should be managed nowadays and discuss the main unsettled issues in the field.

Published
2022
Full Text
View/download PDF

18. Functional characterization of 5p15.33 risk locus in uveal melanoma reveals rs452384 as a functional variant and NKX2.4 as an allele-specific interactor

Author

Derrien, Anne-Céline, primary, Houy, Alexandre, additional, Ganier, Olivier, additional, Dingli, Florent, additional, Ningarhari, Massih, additional, Mobuchon, Lenha, additional, Espejo Díaz, María Isabel, additional, Loew, Damarys, additional, Cassoux, Nathalie, additional, Cussenot, Olivier, additional, Cancel-Tassin, Géraldine, additional, Margueron, Raphael, additional, Noirel, Josselin, additional, Zucman-Rossi, Jessica, additional, Rodrigues, Manuel, additional, and Stern, Marc-Henri, additional

Published
2022
Full Text
View/download PDF

19. Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation

Author

Minoux, Kate, primary, Lassailly, Guillaume, additional, Ningarhari, Massih, additional, Lubret, Henri, additional, El Amrani, Medhi, additional, Canva, Valérie, additional, Truant, Stéphanie, additional, Mathurin, Philippe, additional, Louvet, Alexandre, additional, Lebuffe, Gilles, additional, Goria, Odile, additional, Nguyen-Khac, Eric, additional, Boleslawski, Emmanuel, additional, and Dharancy, Sebastien, additional

Published
2022
Full Text
View/download PDF

20. Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer‐specific and overall mortality: A modeling approach

Author

Ningarhari, Massih, primary, Mourad, Abbas, additional, Delacôte, Claire, additional, Ntandja Wandji, Line‐Carolle, additional, Lassailly, Guillaume, additional, Louvet, Alexandre, additional, Dharancy, Sébastien, additional, Mathurin, Philippe, additional, and Deuffic‐Burban, Sylvie, additional

Published
2022
Full Text
View/download PDF

22. A modelling approach to estimate alcohol-related liver morbidity and mortality in France

Author

Delacôte, Claire, primary, Ntandja Wandji, Line Carolle, additional, Louvet, Alexandre, additional, Bauvin, Pierre, additional, Lassailly, Guillaume, additional, Ningarhari, Massih, additional, Dharancy, Sebastien, additional, Clement, Guillaume, additional, Bruandet, Amelie, additional, Lenne, Xavier, additional, Mathurin, Philippe, additional, and Deuffic-Burban, Sylvie, additional

Published
2022
Full Text
View/download PDF

23. Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma

Author

Gigante, Elia, primary, Hobeika, Christian, additional, Le Bail, Brigitte, additional, Paradis, Valérie, additional, Tougeron, David, additional, Lequoy, Marie, additional, Bouattour, Mohamed, additional, Blanc, Jean-Frédéric, additional, Ganne-Carrié, Nathalie, additional, Tran, Henri, additional, Hollande, Clemence, additional, Allaire, Manon, additional, Amaddeo, Giuliana, additional, Regnault, Helene, additional, Vigneron, Paul, additional, Ronot, Maxime, additional, Elkrief, Laure, additional, Verset, Gontran, additional, Trepo, Eric, additional, Zaanan, Aziz, additional, Ziol, Marianne, additional, Ningarhari, Massih, additional, Calderaro, Julien, additional, Edeline, Julien, additional, and Nault, Jean Charles, additional

Published
2022
Full Text
View/download PDF

26. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.

Author

Gigante, Elia, Hobeika, Christian, Le Bail, Brigitte, Paradis, Valérie, Tougeron, David, Lequoy, Marie, Bouattour, Mohamed, Blanc, Jean Frédéric, Ganne-Carrié, Nathalie, Tran, Henri, Hollande, Clémence, Allaire, Manon, Amaddeo, Giuliana, Regnault, Hélène, Vigneron, Paul, Ronot, Maxime, Elkrief, Laure, Verset, Gontran, Trepo, Eric, Zaanan, Aziz, Ziol, Marianne, Ningarhari, Massih, Calderaro, Julien, Edeline, Julien, Nault, Jean Charles, Gigante, Elia, Hobeika, Christian, Le Bail, Brigitte, Paradis, Valérie, Tougeron, David, Lequoy, Marie, Bouattour, Mohamed, Blanc, Jean Frédéric, Ganne-Carrié, Nathalie, Tran, Henri, Hollande, Clémence, Allaire, Manon, Amaddeo, Giuliana, Regnault, Hélène, Vigneron, Paul, Ronot, Maxime, Elkrief, Laure, Verset, Gontran, Trepo, Eric, Zaanan, Aziz, Ziol, Marianne, Ningarhari, Massih, Calderaro, Julien, Edeline, Julien, and Nault, Jean Charles

Abstract

Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-line systemic treatments in patients with cHCC-CCA., info:eu-repo/semantics/published

Published
2022

27. Corrigendum to: ‘Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target’ [J Hepatol 2021 (74) 1155-1166]

Author

Ningarhari, Massih, primary, Caruso, Stefano, additional, Hirsch, Théo Z., additional, Bayard, Quentin, additional, Franconi, Andrea, additional, Védie, Anne-Laure, additional, Noblet, Bénédicte, additional, Blanc, Jean-Frédéric, additional, Amaddeo, Giuliana, additional, Ganne, Nathalie, additional, Ziol, Marianne, additional, Paradis, Valérie, additional, Guettier, Catherine, additional, Calderaro, Julien, additional, Morcrette, Guillaume, additional, Kim, Youngsoo, additional, MacLeod, A. Robert, additional, Nault, Jean-Charles, additional, Rebouissou, Sandra, additional, and Zucman-Rossi, Jessica, additional

Published
2022
Full Text
View/download PDF

28. Lung Infection Affects Access to Treatment and Short-Term Outcome in Patients With Severe Alcohol-Related Hepatitis Treated With Corticosteroids

Author

Ntandja Wandji, Line Carolle, primary, Ningarhari, Massih, additional, Lemaître, Elise, additional, Khaldi, Marion, additional, Saffers, Pierre, additional, Lollivier, Julien, additional, Lassailly, Guillaume, additional, Dharancy, Sébastien, additional, Mathurin, Philippe, additional, and Louvet, Alexandre, additional

Published
2022
Full Text
View/download PDF

29. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

Author

Gigante, Elia, primary, Hobeika, Christian, additional, Le Bail, Brigitte, additional, Paradis, Valérie, additional, Tougeron, David, additional, Lequoy, Marie, additional, Bouattour, Mohamed, additional, Blanc, Jean-Frederic, additional, Ganne-Carrié, Nathalie, additional, Tran, Henri, additional, Hollande, Clémence, additional, Allaire, Manon, additional, Amaddeo, Giuliana, additional, Regnault, Hélène, additional, Vigneron, Paul, additional, Ronot, Maxime, additional, Elkrief, Laure, additional, Verset, Gontran, additional, Trepo, Eric, additional, Zaanan, Aziz, additional, Ziol, Marianne, additional, Ningarhari, Massih, additional, Calderaro, Julien, additional, Edeline, Julien, additional, and Nault, Jean-Charles, additional

Published
2022
Full Text
View/download PDF

30. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study

Author

Trépo, Eric, primary, Caruso, Stefano, additional, Yang, Jie, additional, Imbeaud, Sandrine, additional, Couchy, Gabrielle, additional, Bayard, Quentin, additional, Letouzé, Eric, additional, Ganne-Carrié, Nathalie, additional, Moreno, Christophe, additional, Oussalah, Abderrahim, additional, Féray, Cyrille, additional, Blanc, Jean Frédéric, additional, Clément, Bruno, additional, Hillon, Patrick, additional, Boursier, Jérôme, additional, Paradis, Valérie, additional, Calderaro, Julien, additional, Gnemmi, Viviane, additional, Nault, Jean-Charles, additional, Guéant, Jean-Louis, additional, Devière, Jacques, additional, Archambeaud, Isabelle, additional, Vitellius, Carole, additional, Turlin, Bruno, additional, Bronowicki, Jean-Pierre, additional, Gustot, Thierry, additional, Sutton, Angela, additional, Ziol, Marianne, additional, Nahon, Pierre, additional, Zucman-Rossi, Jessica, additional, Meiller, Clément, additional, Cao, Qian, additional, Hirsch, Théo Z., additional, Rebouissou, Sandra, additional, Degré, Delphine, additional, Otero Sanchez, Lukas, additional, Rosewick, Nicolas, additional, Quertinmont, Eric, additional, Desille-Dugast, Mireille, additional, François-Vié, Muriel, additional, Moins, Cécile, additional, Leteurtre, Emmanuelle, additional, Lassailly, Guillaume, additional, Ningarhari, Massih, additional, Boleslawski, Emmanuel, additional, and Cottet, Vanessa, additional

Published
2022
Full Text
View/download PDF

31. Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis

Author

Bou Saleh, Mohamed, primary, Louvet, Alexandre, additional, Ntandja-Wandji, Line Carolle, additional, Boleslawski, Emmanuel, additional, Gnemmi, Viviane, additional, Lassailly, Guillaume, additional, Truant, Stéphanie, additional, Maggiotto, François, additional, Ningarhari, Massih, additional, Artru, Florent, additional, Anglo, Emilie, additional, Sancho-Bru, Pau, additional, Corlu, Anne, additional, Argemi, Josepmaria, additional, Dubois-Chevalier, Julie, additional, Dharancy, Sébastien, additional, Eeckhoute, Jérôme, additional, Bataller, Ramon, additional, Mathurin, Philippe, additional, and Dubuquoy, Laurent, additional

Published
2021
Full Text
View/download PDF

32. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target

Author

Ningarhari, Massih, Caruso, Stefano, Hirsch, Théo, Bayard, Quentin, Franconi, Andrea, Védie, Anne-Laure, Noblet, Bénédicte, Blanc, Jean-Frédéric, Amaddeo, Giuliana, Ganne, Nathalie, Ziol, Marianne, Paradis, Valérie, Guettier, Catherine, Calderaro, Julien, Morcrette, Guillaume, Kim, Youngsoo, Macleod, A. Robert, Nault, Jean-Charles, Rebouissou, Sandra, Zucman-Rossi, Jessica, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Beaujon [AP-HP], Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), AP-HP Hôpital universitaire Robert-Debré [Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), HAL-SU, Gestionnaire, École Pratique des Hautes Études (EPHE), and CHU Henri Mondor [Créteil]

Subjects
Antisense oligonucleotides, TERT, Chronic liver disease, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Fibrosis, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, digestive system diseases, Treatment, Telomeres, [SDV.CAN] Life Sciences [q-bio]/Cancer, Liver, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Cancer
Abstract

International audience; Background & Aims: Telomerase activation is the earliest event in hepatocellular carcinoma (HCC) development. Thus, we aimed to elucidate the role of telomere length maintenance during liver carcinogenesis.Methods: Telomere length was measured in the tumor and non-tumor liver tissues of 1,502 patients (978 with HCC) and integrated with TERT alterations and expression, as well as clinical and molecular (analyzed by genome, exome, targeted and/or RNA-sequencing) features of HCC. The preclinical efficacy of anti-TERT antisense oligonucleotides (ASO) was assessed in vitro in 26 cell lines and in vivo in a xenograft mouse model.Results: Aging, liver fibrosis, male sex and excessive alcohol consumption were independent determinants of liver telomere attrition. HCC that developed in livers with long telomeres frequently had wild-type TERT with progenitor features and BAP1 mutations. In contrast, HCC that developed on livers with short telomeres were enriched in the non-proliferative HCC class and frequently had somatic TERT promoter mutations. In HCCs, telomere length is stabilized in a narrow biological range around 5.7 kb, similar to non-tumor livers, by various mechanisms that activate TERT expression. Long telomeres are characteristic of very aggressive HCCs, associated with the G3 transcriptomic subclass, TP53 alterations and poor prognosis. In HCC cell lines, TERT silencing with ASO was efficient in highly proliferative and poorly differentiated cells. Treatment for 3 to 16 weeks induced cell proliferation arrest in 12 cell lines through telomere shortening, DNA damage and activation of apoptosis. The therapeutic effect was also obtained in a xenograft mouse model.Conclusions: Telomere maintenance in HCC carcinogenesis is diverse, and is associated with tumor progression and aggressiveness. The efficacy of anti-TERT ASO treatment in cell lines revealed the oncogenic addiction to TERT in HCC, providing a preclinical rationale for anti-TERT ASO treatment in HCC clinical trials.Lay summary: Telomeres are repeated DNA sequences that protect chromosomes and naturally shorten in most adult cells because of the inactivation of the TERT gene, coding for the telomerase enzyme. Here we show that telomere attrition in the liver, modulated by aging, sex, fibrosis and alcohol, associates with specific clinical and molecular features of hepatocellular carcinoma, the most frequent primary liver cancer. We also show that liver cancer is dependent on TERT reactivation and telomere maintenance, which could be targeted through a novel therapeutic approach called antisense oligonucleotides.

Published
2021
Full Text
View/download PDF

34. Erratum to: “IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis”

Author

Artru, Florent, primary, Bou Saleh, Mohammed, additional, Maggiotto, François, additional, Lassailly, Guillaume, additional, Ningarhari, Massih, additional, Demaret, Julie, additional, Ntandja-Wandji, Line-Carolle, additional, Pais de Barros, Jean-Paul, additional, Labreuche, Julien, additional, Drumez, Elodie, additional, Helou, Doumet Georges, additional, Dharancy, Sébastien, additional, Gantier, Emilie, additional, Périanin, Axel, additional, Chollet-Martin, Sylvie, additional, Bataller, Ramon, additional, Mathurin, Philippe, additional, Dubuquoy, Laurent, additional, and Louvet, Alexandre, additional

Published
2021
Full Text
View/download PDF

35. Real life experience of mycophenolate mofetil monotherapy in liver transplant patients

Author

Lassailly, Guillaume, primary, Dumortier, Jerome, additional, Saint-Marcoux, Franck, additional, El Amrani, Medhi, additional, Boulanger, Juliette, additional, Boleslawski, Emmanuel, additional, Millet, Guillaume, additional, Ningarhari, Massih, additional, Truant, Stephanie, additional, Canva, Valérie, additional, Goria, Odile, additional, Boillot, Olivier, additional, Louvet, Alexandre, additional, Mathurin, Philippe, additional, Lebuffe, Gilles, additional, Pruvot, François-René, additional, Marquet, Pierre, additional, and Dharancy, Sébastien, additional

Published
2021
Full Text
View/download PDF

36. OS-083-YI - Natural history and management of recurrent hepatocellular carcinoma after liver transplantation: a multicenter nationwide study

Author

Ningarhari, Massih, Henry, Camille, Boleslawski, Emmanuel, Besch, Camille, Faitot, François, Assenat, Eric, Herrero, Astrid, Ursic-Bedoya, Jose, Robin, Fabien, Uguen, Thomas, Antonini, Teresa, Erard, Domitille, Radenne, Sylvie, Brusset, Bleuenn, Decaens, Thomas, Allaire, Manon, Conti, Filomena, Barraud, Hélène, Elkrief, Laure, Salamé, Ephrem, Boillot, Olivier, Dumortier, Jérôme, Ntandja Wandji, Line Carolle, Louvet, Alexandre, Mathurin, Philippe, Dharancy, Sebastien, and Lassailly, Guillaume

Published
2023
Full Text
View/download PDF

37. LBO-04 - Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma

Author

Zeng, Qinghe, Klein, Christophe, Caruso, Stefano, Maille, Pascale, Allende, Daniela, Minguez, Beatriz, Iavarone, Massimo, Ningarhari, Massih, Gardini, Andrea Casadei, Pedica, Federica, Rimini, Margherita, perbellini, Riccardo, Boulagnon-Rombi, Camille, Heurgue-berlot, Alexandra, Maggioni, Marco, Rela, Mohd., Vij, Mukul, Baulande, Sylvain, Legoix, Patricia, Lameiras, Sonia, Labgaa, Ismail, Sempoux, Christine, Digkilia, Antonia, Ghaffari-Laleh, Narmin, Kather, Jakob Nikolas, El Nahhas, Omar, Navale, Pooja, Torres, Callie, Su, Tung-Hung, Graham, Rondell, Salcedo, María, Bermúdez, María, Tran, Nguyen H., Pawlotsky, Jean-Michel, Verset, Gontran, Trépo, Eric, Varela, Maria, Castano-Garcia, Andrés, Wendum, Dominique, Amaddeo, Giuliana, Regnault, Helene, Lequoy, Marie, Díaz, Alba, Reig, María, Radu, Pompilia, Dufour, Jean-François, Chan, Stephen, Gopal, Purva, Bruges, Léa, Gnemmi, Viviane, Nault, Jean Charles, Rhee, Hyungjin, Park, Young Nyun, Iñarrairaegui, Mercedes, Argemi, Josep Maria, Sangro, Bruno, D’Alessio, Antonio, Scheiner, Bernhard, Pinato, David J., Pinter, Matthias, Paradis, Valérie, Beaufrère, Aurélie, Peter, Simon, Rimassa, Lorenza, Di Tommaso, Luca, Vogel, Arndt, Michalak, Sophie, Boursier, Jerome, Loménie, Nicolas, Ziol, Marianne, and Calderaro, Julien

Published
2023
Full Text
View/download PDF

38. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis

Author

Lassailly, Guillaume, primary, Caiazzo, Robert, additional, Ntandja-Wandji, Line-Carolle, additional, Gnemmi, Viviane, additional, Baud, Gregory, additional, Verkindt, Helene, additional, Ningarhari, Massih, additional, Louvet, Alexandre, additional, Leteurtre, Emmanuelle, additional, Raverdy, Violeta, additional, Dharancy, Sébastien, additional, Pattou, François, additional, and Mathurin, Philippe, additional

Published
2020
Full Text
View/download PDF

39. IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis

Author

Artru, Florent, primary, Bou Saleh, Mohamed, additional, Maggiotto, François, additional, Lassailly, Guillaume, additional, Ningarhari, Massih, additional, Demaret, Julie, additional, Ntandja-Wandji, Line-Carolle, additional, Pais de Barros, Jean-Paul, additional, Labreuche, Julien, additional, Drumez, Elodie, additional, Helou, Doumet Georges, additional, Dharancy, Sébastien, additional, Gantier, Emilie, additional, Périanin, Axel, additional, Chollet-Martin, Sylvie, additional, Bataller, Ramon, additional, Mathurin, Philippe, additional, Dubuquoy, Laurent, additional, and Louvet, Alexandre, additional

Published
2020
Full Text
View/download PDF

40. NEW INSIGTHS IN CELLULAR MECHANISMS INVOLVED IN THE LIVER REGENERATION DEFECT DESCRIBED IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS

Author

Saleh, Mohamed Bou, Lassailly, Guillaume, Ningarhari, Massih, Gnemmi, Viviane, Maggiotto, Francois, Artru, Florent, Boleslawski, Emmanuel, Anglo, Emilie, Sancho-Bru, Pau, Stephanie Truant, Corlu, Anne, Argemi, Josepmaria, Dharancy, Sebastien, Bataller, Ramon, Mathurin, Philippe, Louvet, Alexandre, Dubuquoy, Laurent, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Nutrition, Métabolismes et Cancer (NuMeCan), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Pittsburgh (PITT), Pennsylvania Commonwealth System of Higher Education (PCSHE), Hôpital Claude Huriez [Lille], CHU Lille, Université Paris 1 Panthéon-Sorbonne (UP1), Service de pathologie [CHU Lille], Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Lille (CHU de Lille), Université Paris Descartes - Paris 5 (UPD5), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas, Partenaires INRAE, CIBER in Epidemiology and Public Health, Institut National de la Recherche Agronomique (INRA)-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], hépatite alcoolique, microbiote intestinal, [SDV]Life Sciences [q-bio], rectocolite hémorragique, maladie de Crohn, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

42. Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study

Author

Delacôte, Claire, Favre, Mathilde, Amrani, Medhi, Ningarhari, Massih, Lemaitre, Elise, Ntandja‐Wandji, Line Carolle, Bauvin, Pierre, Boleslawski, Emmanuel, Millet, Guillaume, Truant, Stephanie, Mathurin, Philippe, Louvet, Alexandre, Canva, Valérie, Lebuffe, Gilles, Pruvot, François René, Dharancy, Sébastien, Lassailly, Guillaume, Di Martino, Vincent, Turco, Célia, Doussot, Alexandre, Chiche, Laurence, Laurent, Christophe, Chermak, Faiza, Hiriart, Jean‐Baptiste, Buchard, Benjamin, Buc, Emmanuel, Dondero, Federica, Sepulveda, Ailton, Roux, Olivier, Francoz, Claire, Bout, Hélène, Holleville, Mathilde, Duvoux, Christophe, Jost, Paul‐Henri, Girard, Edouard, Abba, Julio, Chirica, Mircea, Decaens, Thomas, Mabrut, Jean‐Yves, Lesurtel, Mickael, Antonini, Teresa, Lebosse, Fanny, Poinsot, Domitille, Lambert, Dominique, Gregoire, Emilie, Chopinet, Sophie, Decoster, Claire, Panaro, Fabrizio, Pageaux, Georges‐Philippe, Vachiery‐Lahaye, Florence, Herrero, Astrid, Ursic‐Bedoya, José, Anty, Rodolphe, Gugenheim, Jean, Goumard, Claire, Savier, Eric, Scatton, Olivier, Mazzola, Alessandra, Mallet, Maxime, Conti, Filomena, Boudjema, Karim, Sulpice, Laurent, Bardou Jacquet, Edouard, Jezequel, Caroline, Houssel‐Debry, Pauline, Bergeat, Damien, Bachellier, Philippe, Besch, Camille, Faitot, François, Addeo, Pietro, Michard, Baptiste, Maulat, Charlotte, Muscari, Fabrice, Kamar, Nassim, Venhard, Jean‐Christophe, Salame, Ephrem, Barbier, Louise, Bucur, Petru, Tabchouri, Nicolas, Brunault, Paul, Cherqui, Daniel, Saliba, Faouzi, Coilly, Audrey, Vibert, Eric, Samuel, Didier, and Adam, René

Abstract

Liver transplant (LT) candidates with a body mass index (BMI) over 40 kg/m2have lower access to a liver graft without clear explanation. Thus, we studied the impact of obesity on the waiting list (WL) and aimed to explore graft proposals and refusal. Data between January 2007 and December 2017 were extracted from the French prospective national database: CRISTAL. Competing risk analyses were performed to evaluate predictors of receiving LT. Competitive events were (1) death/WL removal for disease aggravation or (2) improvement. The link between grade obesity, grafts propositions, and reason for refusal was studied. 15,184 patients were analysed: 10,813 transplant, 2847 death/dropout for aggravation, 748 redirected for improvement, and 776 censored. Mortality/dropout were higher in BMI over 35 (18% vs. 14% 1 year after listing) than in other candidates. In multivariate analysis, BMI>35, age, hepatic encephalopathy, and ascites were independent predictors of death/dropout. Candidates with a BMI ≥ 35 kg/m2had reduced access to LT, without differences in graft proposals. However, grafts refusal was more frequent especially for ‘morphological incompatibility’ (14.9% vs. 12.7% p< 0.01). BMI over 35 kg/m2reduces access to LT with increased risk of dropout and mortality. Increased mortality and dropout could be due to a lower access to liver graft secondary to increased graft refusal for morphological incompatibility.

Published
2022
Full Text
View/download PDF

43. Histoire naturelle et prise en charge du carcinome hépatocellulaire sur foie non cirrhotique.

Author

Benkhelil, Sarra, Ningarhari, Massih, Boleslawski, Emmanuel, Lassailly, Guillaume, Mathurin, Philippe, and Dharancy, Sébastien

Abstract

Résumé: Le carcinome hépatocellulaire se développe dans 20 à 30 % des cas sur foie non cirrhotique, le plus souvent dans les pays occidentaux sur hépatopathie chronique d'origine métabolique. Le carcinome hépatocellulaire sur foie non cirrhotique constitue une entité particulière. Il touche des sujets plus âgés avec une prédominance masculine moins marquée, est découvert sur des symptômes cliniques à un stade plus tardif qu'en cas de cirrhose, son diagnostic est histologique et son traitement curatif de référence est la résection chirurgicale. Sa découverte tardive constitue une difficulté dans l'évaluation pronostique comparativement au carcinome hépatocellulaire développé sur cirrhose. Hepatocellular carcinoma develops in 20 to 30% of cases in non-cirrhotic liver, most often in Western countries on metabolic-related chronic liver disease. Hepatocellular carcinoma in non-cirrhotic liver constitutes a particular entity. It affects older subjects with a less marked male predominance, is discovered on clinical symptoms at a later stage than in cirrhosis, its diagnosis is histological and its standard curative treatment is surgical resection. Its late discovery constitutes a difficulty in the prognostic evaluation compared to hepatocellular carcinoma developed on cirrhosis. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.

Author

Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Ziol M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, and Zucman-Rossi J

Subjects
Cell Line, Tumor, Drug Discovery, Ethanol metabolism, Humans, Liver Cirrhosis etiology, Liver Cirrhosis metabolism, Oncogene Addiction, Sex Factors, Telomerase genetics, Aging physiology, Carcinogenesis genetics, Carcinoma, Hepatocellular genetics, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular therapy, Liver Neoplasms genetics, Liver Neoplasms metabolism, Liver Neoplasms pathology, Oligonucleotides, Antisense pharmacology, Telomerase metabolism, Telomere Homeostasis drug effects, Telomere Homeostasis physiology
Abstract

Background & Aims: Telomerase activation is the earliest event in hepatocellular carcinoma (HCC) development. Thus, we aimed to elucidate the role of telomere length maintenance during liver carcinogenesis., Methods: Telomere length was measured in the tumor and non-tumor liver tissues of 1,502 patients (978 with HCC) and integrated with TERT alterations and expression, as well as clinical and molecular (analyzed by genome, exome, targeted and/or RNA-sequencing) features of HCC. The preclinical efficacy of anti-TERT antisense oligonucleotides (ASO) was assessed in vitro in 26 cell lines and in vivo in a xenograft mouse model., Results: Aging, liver fibrosis, male sex and excessive alcohol consumption were independent determinants of liver telomere attrition. HCC that developed in livers with long telomeres frequently had wild-type TERT with progenitor features and BAP1 mutations. In contrast, HCC that developed on livers with short telomeres were enriched in the non-proliferative HCC class and frequently had somatic TERT promoter mutations. In HCCs, telomere length is stabilized in a narrow biological range around 5.7 kb, similar to non-tumor livers, by various mechanisms that activate TERT expression. Long telomeres are characteristic of very aggressive HCCs, associated with the G3 transcriptomic subclass, TP53 alterations and poor prognosis. In HCC cell lines, TERT silencing with ASO was efficient in highly proliferative and poorly differentiated cells. Treatment for 3 to 16 weeks induced cell proliferation arrest in 12 cell lines through telomere shortening, DNA damage and activation of apoptosis. The therapeutic effect was also obtained in a xenograft mouse model., Conclusions: Telomere maintenance in HCC carcinogenesis is diverse, and is associated with tumor progression and aggressiveness. The efficacy of anti-TERT ASO treatment in cell lines revealed the oncogenic addiction to TERT in HCC, providing a preclinical rationale for anti-TERT ASO treatment in HCC clinical trials., Lay Summary: Telomeres are repeated DNA sequences that protect chromosomes and naturally shorten in most adult cells because of the inactivation of the TERT gene, coding for the telomerase enzyme. Here we show that telomere attrition in the liver, modulated by aging, sex, fibrosis and alcohol, associates with specific clinical and molecular features of hepatocellular carcinoma, the most frequent primary liver cancer. We also show that liver cancer is dependent on TERT reactivation and telomere maintenance, which could be targeted through a novel therapeutic approach called antisense oligonucleotides., Competing Interests: Conflict of interest Youngsoo Kim and A. Robert MacLeod are part of Ionis Pharmaceuticals, Carlsbad, CA, USA. Please refer to the accompanying ICMJE disclosure forms for further details., (Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results